SUPPORT AGREEMENTSupport Agreement • January 5th, 2017 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Delaware
This SUPPORT AGREEMENT (this “Agreement”), dated as of January 5, 2017, is by and among Achieve Life Science, Inc., a Delaware corporation (the “Company”, or “Ash”), and the equityholders of OncoGenex Pharmaceuticals, Inc., a Delaware corporation (“Arrow”), set forth on Schedule A hereto (each, an “Equityholder” and collectively, the “Equityholders”).
SUPPORT AGREEMENTSupport Agreement • January 5th, 2017 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Delaware
This SUPPORT AGREEMENT (this “Agreement”), dated as of January 5, 2017, is by and among OncoGenex Pharmaceuticals, Inc., a Delaware corporation (the “Company”, or “Arrow”), and the equityholders of Achieve Life Science, Inc., a Delaware corporation (“Ash”), set forth on Schedule A hereto (each, an “Equityholder” and collectively, the “Equityholders”).
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION by and among: ONCOGENEX PHARMACEUTICALS, INC., a Delaware corporation; ASH ACQUISITION SUB, INC., a Delaware corporation; ASH ACQUISITION SUB 2, INC., a Delaware corporation; and ACHIEVE LIFE SCIENCE,...Merger Agreement • January 5th, 2017 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Delaware
THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of January 5, 2017, by and among ONCOGENEX PHARMACEUTICALS, INC., a Delaware corporation (“Arrow”), ASH ACQUISITION SUB, INC., a Delaware corporation (“Merger Sub 1”), ASH ACQUISITION SUB 2, INC., a Delaware corporation (“Merger Sub 2”; together with Merger Sub 1, “Merger Subs”), and ACHIEVE LIFE SCIENCE, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
